Canada's BioSyent Q2 revenue jumps 95% following Oral Health acquisition

Biosyent

20/08/2026 22:15

Overview
Canada specialty healthcare firm's Q2 revenue rose 95% yr/yr, driven by Oral Health acquisition
Q2 net income after tax increased 41% yr/yr; fully diluted EPS rose 39%
Company repurchased and cancelled 218,500 shares under Normal Course Issuer Bid in H1 2026

Outlook
Company did not provide specific financial guidance for the current quarter or full year

Result Drivers
ORAL HEALTH SEGMENT - First full quarter of Oral Health segment following acquisition contributed $8.2 mln in sales and $1.1 mln in net income after tax (before amortization expense)
PHARMACEUTICAL SEGMENT GROWTH - Continued growth in existing Pharmaceutical segment in Canada and internationally supported overall results, per CEO René Goehrum

Company press release: ID:nGNX1x3W1K

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
 
C$0.25
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for BioSyent Inc is C$18.00, about 22% above its August 19 closing price of C$14.75
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Reuters Recommended Reads
Aug 20 - Canada's Perimeter Medical Imaging AI Q2 loss narrows on lower expenses
Aug 18 - Switzerland's Basilea H1 revenue rises on Cresemba demand; ups 2026 profit outlook
Aug 18 - China's Ping An Healthcare H1 revenue profit jumps on corporate client base expansion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)